Compounds with therapeutic potential against novel respiratory 2019 coronavirus

Antimicrobial Agents and Chemotherapy

Volumn 64, Issue 5, 2020, Pages

  Martinez, Miguel Angel ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Antiviral agents; Coronavirus; SARS CoV 2

Indexed keywords

ANTIVIRUS AGENT; BETA INTERFERON; LOPINAVIR PLUS RITONAVIR; REMDESIVIR; ADENOSINE PHOSPHATE; ALANINE; CORONAVIRUS SPIKE GLYCOPROTEIN; LOPINAVIR; LOPINAVIR-RITONAVIR DRUG COMBINATION; MONOCLONAL ANTIBODY; RIBAVIRIN; RITONAVIR; SPIKE PROTEIN, SARS-COV-2;

ANTIVIRAL THERAPY; ARTICLE; CALLITRICHINAE; CORONAVIRUS DISEASE 2019; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MORTALITY RATE; NONHUMAN; PRIORITY JOURNAL; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; TISSUE CULTURE; VIRUS ENTRY; VIRUS INFECTION; ANIMAL; BETACORONAVIRUS; CLINICAL TRIAL (TOPIC); CORONAVIRUS INFECTION; DRUG COMBINATION; DRUG EFFECT; PANDEMIC; PASSIVE IMMUNIZATION; SARS CORONAVIRUS; TRANSGENIC MOUSE; VIRUS PNEUMONIA;

ADENOSINE MONOPHOSPHATE; ALANINE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BETACORONAVIRUS; CLINICAL TRIALS AS TOPIC; CORONAVIRUS INFECTIONS; DRUG COMBINATIONS; HUMANS; IMMUNIZATION, PASSIVE; INTERFERON-BETA; LOPINAVIR; MICE, TRANSGENIC; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PANDEMICS; PNEUMONIA, VIRAL; RIBAVIRIN; RITONAVIR; SARS VIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS;

EID: 85082422978     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00399-20     Document Type: Article

References (46)

1. WHO. 2020. Novel coronavirus (2019-nCoV) situation reports. World Health Organization. http://www.who.int/emergencies/diseases/novel -coronavirus-2019/situation-reports/.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497-506. https://doi.org/10.1016/S0140-6736(20)30183-5.
3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 395:507-513. https://doi.org/10.1016/S0140-6736(20)30211-7.
4. Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, Xing F, Liu J, Yip CCY, Poon RWS, Tsoi HW, Lo SKF, Chan KH, Poon VKM, Chan WM, Ip JD, Cai JP, Cheng VCC, Chen H, Hui CKM, Yuen KY. 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet 395: 514-523. https://doi.org/10.1016/S0140-6736(20)30154-9.
5. Gorbalenya AE. 2020. Severe acute respiratory syndrome-related coronavirus: The species and its viruses-a statement of the Coronavirus Study Group. bioRxiv https://doi.org/10.1101/2020.02.07.937862.
6. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. 17 February 2020, posting date. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)- China, 2020. Zhonghua Liu Xing Bing Xue Za Zhi (In Chinese.) https://doi.org/10.3760/cma.j.issn.0254-6450.2020.02.003.
7. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus A, Fouchier R. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:1814 -1820. https://doi.org/10.1056/NEJMoa1211721.
8. Drosten C, Günther S, Preiser W, Van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RAM, Berger A, Burguière AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Müller S, Rickerts V, Stürmer M, Vieth S, Klenk HD, Osterhaus A, Schmitz H, Doerr HW. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348:1967-1976. https://doi.org/10.1056/NEJMoa030747.
9. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, Chen H-D, Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang X, Zheng X-S, Zhao K, Chen Q-J, Deng F, Liu L-L, Yan B, Zhan F-X, Wang Y-Y, Xiao G-F, Shi Z-L. 3 February 2020, posting date. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature https://doi.org/10.1038/s41586-020-2012-7.
10. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. 2020. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 395:565-574. https://doi.org/10.1016/S0140-6736(20)30251-8.
11. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. 2020. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727-733. https://doi.org/10.1056/NEJMoa2001017.
12. Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC. 2019. Advances in respiratory virus therapeutics - a meeting report from the 6th ISIRV Antiviral Group conference. Antiviral Res 167:45- 67. https://doi.org/10.1016/j.antiviral.2019.04.006.
13. Bradwell K, Combe M, Domingo-Calap P, Sanjuán R. 2013. Correlation between mutation rate and genome size in riboviruses: Mutation rate of bacteriophage Q. Genetics 195:243-251. https://doi.org/10.1534/genetics.113.154963.
14. Wang C, Horby PW, Hayden FG, Gao GF. 2020. A novel coronavirus outbreak of global health concern. Lancet 395:470-473. https://doi.org/10.1016/S0140-6736(20)30185-9.
15. Chao L. 1990. Fitness of RNA virus decreased by Muller's ratchet. Nature 348:454-455. https://doi.org/10.1038/348454a0.
16. Duarte E, Clarke D, Moya A, Domingo E, Holland J. 1992. Rapid fitness losses in mammalian RNA virus clones due to Muller's ratchet. Proc Natl Acad Sci U S A 89:6015- 6019. https://doi.org/10.1073/pnas.89.13.6015.
17. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, MacKman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS. 28 June 2017, posting date. Broadspectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med https://doi.org/10.1126/scitranslmed.aal3653.
18. Mulangu S, Dodd LE, Davey RT, Mbaya OT, Proschan M, Mukadi D, Manzo ML, Nzolo D, Oloma AT, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Clifford Lane H, Muyembe-Tamfum JJ, Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolskis M, Sow Y, Tierney J, Sivapalasingam S, Holman W, Gettinger N, Vallée D, et al. 2019. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 381:2293-2303. https://doi.org/10.1056/NEJMoa1910993.
19. Brown AJ, Won JJ, Graham RL, Dinnon KH, Sims AC, Feng JY, Cihlar T, Denison MR, Baric RS, Sheahan TP. 2019. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res 169: 104541. https://doi.org/10.1016/j.antiviral.2019.104541.
20. Cockrell AS, Yount BL, Scobey T, Jensen K, Douglas M, Beall A, Tang XC, Marasco WA, Heise MT, Baric RS. 2016. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat Microbiol 2:16226. https://doi.org/10.1038/nmicrobiol.2016.226.
21. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR. 2018. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9:e00221-18. https://doi.org/10.1128/mBio.00221-18.
22. de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T, Feldmann H. 13 February 2020, posting date. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A https://doi.org/10.1073/pnas.1922083117.
23. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, Kao RYT, Poon LLM, Wong CLP, Guan Y, Peiris JSM, Yuen KY; HKU/UCH SARS Study Group. 2004. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax 59:252-256. https://doi.org/10.1136/thorax.2003.012658.
24. Chan JFW, Yao Y, Yeung ML, Deng W, Bao L, Jia L, Li F, Xiao C, Gao H, Yu P, Cai JP, Chu H, Zhou J, Chen H, Qin C, Yuen KY. 2015. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 212:1904 -1913. https://doi.org/10.1093/infdis/jiv392.
25. Chan JFW, Chan KH, Kao RYT, To KKW, Zheng BJ, Li CPY, Li PTW, Dai J, Mok FKY, Chen H, Hayden FG, Yuen KY. 2013. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 67:606-616. https://doi.org/10.1016/j.jinf.2013.09.029.
26. De Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, Van Nieuwkoop S, Bestebroer TM, Van Den Hoogen BG, Neyts J, Snijder EJ. 2014. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58: 4875-4884. https://doi.org/10.1128/AAC.03011-14.
27. Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, Olinger GG, Frieman MB, Holbrook MR, Jahrling PB, Hensley L. 2014. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 95:571-577. https://doi.org/10.1099/vir.0.061911-0.
28. Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, Kojan S, Al Jeraisy M, Deeb AM, Assiri AM, Al-Hameed F, Al Saedi A, Mandourah Y, Almekhlafi GA, Sherbeeni NM, Elzein FE, Memon J, Taha Y, Almotairi A, Maghrabi KA, Qushmaq I, Al Bshabshe A, Kharaba A, Shalhoub S, Jose J, Fowler RA, Hayden FG, Hussein MA, Martin GS, Schoenfeld DA, Walmsley SL, Carson S, Al Harbi S, Al Jeraisy M, Al Muhaidib M, Musharaf S, Al Anizi H, Dael R, Al Mazroa M, Asiri A, Memish ZA, Ghazal SS, Alfaraj SH, Al Harthy A, Al Sulaiman M, Mady A, et al. 2018. Treatment of Middle East respiratory syndrome with a combination of lopinavirritonavir and interferon-β1b (MIRACLE trial): Study protocol for a randomized controlled trial. Trials 19:81. https://doi.org/10.1186/s13063 -017-2427-0.
29. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE, Bauer L, Sellers S, Porter D, Feng JY, Cihlar T, Jordan R, Denison MR, Baric RS. 2020. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 11:222. https://doi.org/10.1038/s41467-019-13940-6.
30. Falzarano D, De Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, Brining D, Bushmaker T, Martellaro C, Baseler L, Benecke AG, Katze MG, Munster VJ, Feldmann H. 2013. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 19:1313-1317. https://doi.org/10.1038/nm.3362.
31. Arabi YM, Shalhoub S, Omari AA, Mandourah Y, Al-Hameed F, Sindi A, Alraddadi B, Motairi AA, Khatib KA, Mommin AA, Qushmaq IA, Mady A, Solaiman O, Aithan AA, Balkhy HH, Al-Raddadi R, Rajab A, Mekhlafi G, Harthy AA, Kharaba A, Al-Jabbary A, Pinto R, Sadat M, Al Mutairi H, Al Qasim E, Jose J, Deeb AM, Merson L, Hayden FG, Fowler R, Aldawood A. 2017. Effect of ribavirin and interferon on the outcome of critically ill patients with MERS. Am J Respir Crit Care Med 195:A6067. https://doi.org/10.1164/rccm.201706-1172OC.
32. McBride JM, Lim JJ, Burgess T, Deng R, Derby MA, Maia M, Horn P, Siddiqui O, Sheinson D, Chen-Harris H, Newton EM, Fillos D, Nazzal D, Rosenberger CM, Ohlson MB, Lambkin-Williams R, Fathi H, Harris JM, Tavela JA. 2017. Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza a virus challenge model. Antimicrob Agents Chemother 61: E01154-17. https://doi.org/10.1128/AAC.01154-17.
33. Hershberger E, Sloan S, Narayan K, Hay CA, Smith P, Engler F, Jeeninga R, Smits S, Trevejo J, Shriver Z, Oldach D. 2019. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebocontrolled study. EBioMedicine 40:574 -582. https://doi.org/10.1016/j.ebiom.2018.12.051.
34. Beigel JH, Voell J, Kumar P, Raviprakash K, Wu H, Jiao JA, Sullivan E, Luke T, Davey RT. 2018. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: A phase 1 randomised, double-blind, single-doseescalation study. Lancet Infect Dis 18:410 - 418. https://doi.org/10.1016/S1473-3099(18)30002-1.
35. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. 2006. Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann Intern Med 145:599-609. https://doi.org/10.7326/0003-4819-145-8-200610170-00139.
36. Hung IFN, To KKW, Lee CK, Lee KL, Yan WW, Chan K, Chan WM, Ngai CW, Law KI, Chow FL, Liu R, Lai KY, Candy CC, Liu SH, Chan KH, Lin CK, Yuen KY. 2013. Hyperimmune IV immunoglobulin treatment: A multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 144:464-473. https://doi.org/10.1378/chest.12-2907.
37. Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden FG, Al-Omari A, Al-Hameed FM, Taha Y, Shindo N, Whitehead J, Merson L, AlJohani S, Al-Khairy K, Carson G, Luke TC, Hensley L, Al-Dawood A, Al-Qahtani S, Modjarrad K, Sadat M, Rohde G, Leport C, Fowler R. 19 November 2015, posting date. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: A study protocol. Springerplus https://doi.org/10.1186/s40064-015-1490-9.
38. Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM, Karp CL, McAlees J, Gioannini TL, Weiss J, Chen WH, Ernst RK, Rossignol DP, Gusovsky F, Blanco JCG, Vogel SN. 2013. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 497:498 -502. https://doi.org/10.1038/nature12118.
39. Perrin-Cocon L, Aublin-Gex A, Sestito SE, Shirey KA, Patel MC, André P, Blanco JC, Vogel SN, Peri F, Lotteau V. 2017. TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection. Sci Rep 7:40791. https://doi.org/10.1038/srep40791.
40. Piao W, Shirey KA, Ru LW, Lai W, Szmacinski H, Snyder GA, Sundberg EJ, Lakowicz JR, Vogel SN, Toshchakov VY. 2015. A decoy peptide that disrupts TIRAP recruitment to TLRs is protective in a murine model of influenza. Cell Rep 11:1941-1952. https://doi.org/10.1016/j.celrep.2015.05.035.
41. Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. 2016. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 3:CD010406. https://doi.org/10.1002/14651858.CD010406.pub2.
42. Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, Jose J, Pinto R, Al-Omari A, Kharaba A, Almotairi A, Al Khatib K, Alraddadi B, Shalhoub S, Abdulmomen A, Qushmaq I, Mady A, Mady O, Al-Aithan AM, Al-Raddadi R, Ragab A, Balkhy HH, Balkhy A, Deeb AM, Al Mutairi H, Al-Dawood A, Merson L, Hayden FG, Fowler RA; Saudi Critical Care Trial Group. 2018. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 197:757-767. https://doi.org/10.1164/rccm.201706-1172OC.
43. Glowacka I, Bertram S, Muller MA, Allen P, Soilleux E, Pfefferle S, Steffen I, Tsegaye TS, He Y, Gnirss K, Niemeyer D, Schneider H, Drosten C, Pohlmann S. 2011. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol 85:4122- 4134. https://doi.org/10.1128/JVI.02232-10.
44. Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. 2012. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol 86:6537- 6545. https://doi.org/10.1128/JVI.00094-12.
45. Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R, Nunneley JW, Barnard D, Pöhlmann S, McKerrow JH, Renslo AR, Simmons G. 2015. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res 116: 76-84. https://doi.org/10.1016/j.antiviral.2015.01.011.
46. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. 4 March 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. https://doi.org/10.1016/j.cell.2020.02.052.